Alterity Therapeutics Ltd (PRNAF) — SEC Filings
Alterity Therapeutics Ltd (PRNAF) — 50 SEC filings. Latest: 6-K (Nov 24, 2025). Includes 49 6-K, 1 20-F.
View Alterity Therapeutics Ltd on SEC EDGAR
Overview
Alterity Therapeutics Ltd (PRNAF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 24, 2025: Alterity Therapeutics Ltd. filed a Form 6-K on November 24, 2025, to incorporate by reference into several of its Registration Statements on Form S-8 and Form F-3. The filing includes Exhibit 99.1, which is a Final Director's Interest notice. The company, formerly known as Prana Biotechnology Ltd, i
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bullish, 47 neutral, 1 mixed. The dominant filing sentiment for Alterity Therapeutics Ltd is neutral.
Filing Type Overview
Alterity Therapeutics Ltd (PRNAF) has filed 49 6-K, 1 20-F with the SEC between Mar 2025 to Nov 2025.
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of PRNAF's 47 recent filings, 1 were flagged as high-risk, 17 as medium-risk, and 29 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- David Stamler
Industry Context
Alterity Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on developing treatments for neurodegenerative diseases like Parkinson's. This sector is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success is heavily dependent on scientific innovation, successful clinical trial outcomes, and the ability to secure substantial funding.
Top Tags
registration-statement (26) · filing-update (20) · sec-filing (6) · substantial-holding (5) · procedural (4) · disclosure (3) · 6-K (3) · biotech (3) · securities-application (3) · clinical-trial (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Capital Raised | $20.0M | Funds secured through a strategic placement to support company operations and development. |
| Ordinary Shares Outstanding | 9,127,370,686 | As of June 30, 2025, indicating a large share base for a development-stage company. |
| Ordinary Shares per ADS | 600 | Each ADS represents 600 ordinary shares, impacting per-share valuation for U.S. investors. |
| Fiscal Year End | 2025-06-30 | The period covered by this annual report. |
| Filing Date | 2025-08-29 | Date the 20-F was filed with the SEC. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Alterity Therapeutics Ltd (PRNAF)?
Alterity Therapeutics Ltd has 50 recent SEC filings from Mar 2025 to Nov 2025, including 49 6-K, 1 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PRNAF filings?
Across 50 filings, the sentiment breakdown is: 2 bullish, 47 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Alterity Therapeutics Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Alterity Therapeutics Ltd (PRNAF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Alterity Therapeutics Ltd?
Financial highlights for Alterity Therapeutics Ltd are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for PRNAF?
The investment thesis for PRNAF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Alterity Therapeutics Ltd?
Key executives identified across Alterity Therapeutics Ltd's filings include David Stamler.
What are the main risk factors for Alterity Therapeutics Ltd stock?
Of PRNAF's 47 assessed filings, 1 were flagged high-risk, 17 medium-risk, and 29 low-risk.
What are recent predictions and forward guidance from Alterity Therapeutics Ltd?
Forward guidance and predictions for Alterity Therapeutics Ltd are extracted from SEC filings as they are enriched.